Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition.

Solit DB, Santos E, Pratilas CA, Lobo J, Moroz M, Cai S, Blasberg R, Sebolt-Leopold J, Larson S, Rosen N.

Cancer Res. 2007 Dec 1;67(23):11463-9.

PMID:
18056475
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.

McKinley ET, Smith RA, Zhao P, Fu A, Saleh SA, Uddin MI, Washington MK, Coffey RJ, Manning HC.

J Nucl Med. 2013 Mar;54(3):424-30. doi: 10.2967/jnumed.112.108456. Epub 2013 Jan 22.

PMID:
23341544
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901.

Leyton J, Smith G, Lees M, Perumal M, Nguyen QD, Aigbirhio FI, Golovko O, He Q, Workman P, Aboagye EO.

Mol Cancer Ther. 2008 Sep;7(9):3112-21. doi: 10.1158/1535-7163.MCT-08-0264.

PMID:
18790789
[PubMed - indexed for MEDLINE]
Free Article
4.

BRAF mutation predicts sensitivity to MEK inhibition.

Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N.

Nature. 2006 Jan 19;439(7074):358-62. Epub 2005 Nov 6.

PMID:
16273091
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.

Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N.

Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14903-8. doi: 10.1073/pnas.1008990107. Epub 2010 Jul 28.

PMID:
20668238
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.

Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A, Foà R, Tafuri A, Cognetti F, Anichini A, Zupi G, Milella M.

Neoplasia. 2009 Aug;11(8):720-31.

PMID:
19649202
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, Fagin JA.

J Clin Endocrinol Metab. 2008 Jun;93(6):2194-201. doi: 10.1210/jc.2007-2825. Epub 2008 Apr 1.

PMID:
18381570
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.

Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, Saborowski M, Kastenhuber E, Fellmann C, Ohara K, Morikami K, Miura T, Lukacs C, Ishii N, Lowe S, Rosen N.

Cancer Cell. 2014 May 12;25(5):697-710. doi: 10.1016/j.ccr.2014.03.011. Epub 2014 Apr 17.

PMID:
24746704
[PubMed - indexed for MEDLINE]
9.

MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells.

Falck Miniotis M, Arunan V, Eykyn TR, Marais R, Workman P, Leach MO, Beloueche-Babari M.

Cancer Res. 2013 Jul 1;73(13):4039-49. doi: 10.1158/0008-5472.CAN-12-1969. Epub 2013 May 2.

PMID:
23639941
[PubMed - indexed for MEDLINE]
Free Article
10.

MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.

Henderson YC, Chen Y, Frederick MJ, Lai SY, Clayman GL.

Mol Cancer Ther. 2010 Jul;9(7):1968-76. doi: 10.1158/1535-7163.MCT-10-0062. Epub 2010 Jun 29.

PMID:
20587665
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, Stern H, Choo E, Murray L, Friedman LS, Belvin M.

Cancer Res. 2009 Apr 1;69(7):3042-51. doi: 10.1158/0008-5472.CAN-08-3563. Epub 2009 Mar 10.

PMID:
19276360
[PubMed - indexed for MEDLINE]
Free Article
12.

MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.

Trejo CL, Juan J, Vicent S, Sweet-Cordero A, McMahon M.

Cancer Res. 2012 Jun 15;72(12):3048-59. doi: 10.1158/0008-5472.CAN-11-3649. Epub 2012 Apr 17.

PMID:
22511580
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.

Jalili A, Wagner C, Pashenkov M, Pathria G, Mertz KD, Widlund HR, Lupien M, Brunet JP, Golub TR, Stingl G, Fisher DE, Ramaswamy S, Wagner SN.

J Natl Cancer Inst. 2012 Nov 7;104(21):1673-9. doi: 10.1093/jnci/djs373. Epub 2012 Sep 20.

PMID:
22997239
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.

Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M, Nelkin BD.

J Clin Endocrinol Metab. 2007 Dec;92(12):4712-8. Epub 2007 Sep 18.

PMID:
17878251
[PubMed - indexed for MEDLINE]
15.

Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.

Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Müller M, Langer O, Wacheck V.

Clin Cancer Res. 2011 Aug 15;17(16):5322-32. doi: 10.1158/1078-0432.CCR-10-1659. Epub 2011 Jun 28.

PMID:
21712451
[PubMed - indexed for MEDLINE]
Free Article
16.

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.

Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.

Clin Cancer Res. 2006 Mar 15;12(6):1785-93.

PMID:
16551863
[PubMed - indexed for MEDLINE]
Free Article
17.

RAF265 inhibits the growth of advanced human melanoma tumors.

Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A.

Clin Cancer Res. 2012 Apr 15;18(8):2184-98. doi: 10.1158/1078-0432.CCR-11-1122. Epub 2012 Feb 20. Erratum in: Clin Cancer Res. 2012 Aug 15;18(16):4475.

PMID:
22351689
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S.

Nature. 2010 Mar 18;464(7287):431-5. doi: 10.1038/nature08833. Epub 2010 Feb 3.

PMID:
20130576
[PubMed - indexed for MEDLINE]
19.

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, Zanzonico P, Larson SM, Refetoff S, Ghossein R, Fagin JA.

J Clin Invest. 2011 Dec;121(12):4700-11. doi: 10.1172/JCI46382. Epub 2011 Nov 21.

PMID:
22105174
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.

Leyton J, Alao JP, Da Costa M, Stavropoulou AV, Latigo JR, Perumal M, Pillai R, He Q, Atadja P, Lam EW, Workman P, Vigushin DM, Aboagye EO.

Cancer Res. 2006 Aug 1;66(15):7621-9.

PMID:
16885362
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk